Citadel Advisors’s Cellectis CLLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,100
| Closed | -$5.58K | – | 14582 |
|
|
2024
Q4 | $5.58K | Sell |
3,100
-2,800
| -47% | -$5.22K | ﹤0.01% | 13853 |
|
|
2024
Q3 | $12.6K | Buy |
5,900
+3,100
| +111% | +$6.73K | ﹤0.01% | 13097 |
|
|
2024
Q2 | $5.24K | Buy |
+2,800
| New | +$7.34K | ﹤0.01% | 13421 |
|
|
2024
Q1 | – | Sell |
-500
| Closed | -$1.54K | – | 14637 |
|
|
2023
Q4 | $1.54K | Sell |
500
-2,500
| -83% | -$5.93K | ﹤0.01% | 13808 |
|
|
2023
Q3 | $4.74K | Sell |
3,000
-2,300
| -43% | -$4.49K | ﹤0.01% | 13456 |
|
|
2023
Q2 | $10.4K | Buy |
+5,300
| New | +$10.2K | ﹤0.01% | 13203 |
|
|
2023
Q1 | – | Sell |
-700
| Closed | -$1.47K | – | 14798 |
|
|
2022
Q4 | $1.47K | Buy |
+700
| New | +$1.59K | ﹤0.01% | 14468 |
|
|
2022
Q2 | – | Sell |
-14,600
| Closed | -$66K | – | 12981 |
|
|
2022
Q1 | $66K | Sell |
14,600
-6,500
| -31% | -$35.8K | ﹤0.01% | 12613 |
|
|
2021
Q4 | $171K | Buy |
21,100
+4,700
| +29% | +$46.2K | ﹤0.01% | 12088 |
|
|
2021
Q3 | $207K | Buy |
16,400
+2,600
| +19% | +$36K | ﹤0.01% | 11915 |
|
|
2021
Q2 | $213K | Buy |
+13,800
| New | +$232K | ﹤0.01% | 12019 |
|
|
2021
Q1 | – | Sell |
-8,500
| Closed | -$230K | – | 13206 |
|
|
2020
Q4 | $230K | Buy |
+8,500
| New | +$191K | ﹤0.01% | 9528 |
|
|
2020
Q3 | – | Sell |
-14,900
| Closed | -$265K | – | 10129 |
|
|
2020
Q2 | $265K | Buy |
14,900
+4,200
| +39% | +$63.9K | ﹤0.01% | 8106 |
|
|
2020
Q1 | $98K | Buy |
+10,700
| New | +$160K | ﹤0.01% | 8645 |
|
|
2019
Q3 | – | Sell |
-18,700
| Closed | -$292K | – | 9208 |
|
|
2019
Q2 | $292K | Sell |
18,700
-6,600
| -26% | -$118K | ﹤0.01% | 7624 |
|
|
2019
Q1 | $464K | Buy |
25,300
+10,100
| +66% | +$179K | ﹤0.01% | 6914 |
|
|
2018
Q4 | $253K | Buy |
15,200
+1,500
| +11% | +$34.8K | ﹤0.01% | 7525 |
|
|
2018
Q3 | $387K | Buy |
+13,700
| New | +$394K | ﹤0.01% | 7135 |
|
|
2018
Q1 | – | Sell |
-10,200
| Closed | -$297K | – | 8311 |
|
|
2017
Q4 | $297K | Sell |
10,200
-1,200
| -11% | -$32.7K | ﹤0.01% | 6479 |
|
|
2017
Q3 | $324K | Sell |
11,400
-7,400
| -39% | -$191K | ﹤0.01% | 5948 |
|
|
2017
Q2 | $485K | Buy |
18,800
+5,300
| +39% | +$127K | ﹤0.01% | 5153 |
|
|
2017
Q1 | $324K | Buy |
+13,500
| New | +$284K | ﹤0.01% | 5778 |
|
Other funds holding CLLS
BGI
LFCM
NAMI
Citadel Advisors's CLLS Position: Q2 2026 in Review
Citadel Advisors sold out of Cellectis (CLLS) in Q2 2026, closing a stake of 44,315 shares — an estimated $140K sold.
Citadel Advisors first reported a position in CLLS in Q1 2015 and held it in 40 quarters. The position peaked at $8.53M in Q4 2019. 27 funds tracked by Wall St. Rank hold CLLS as of Q2 2026.
- Citadel Advisors reported no remaining Cellectis position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 44,315 Cellectis shares in Q2 2026, an estimated $140K.
- Citadel Advisors first reported a position in Cellectis in Q1 2015 and held it in 40 quarters.
- Citadel Advisors's Cellectis position peaked at $8.53M in Q4 2019.
- 27 funds tracked by Wall St. Rank held Cellectis as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.